GSE208184
dBET57 exerts anti-cancer effects in neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, which is derived from primordial neural crest cells. dBET57, a new cereblon (CRBN) based inhibitor developed by PROTAC technology. It binds to the BET protein families BRD2, BRD3, and BRD4, which are recruited to the proteasome system for selective ubiquitination degradation. However, the function of dBET57 has not been assessed in NB models so far. In the present study, RNA-seq analysis was performed to explore the effect of dBET57 on NB cells. Overall design: mRNA profiles of SK-N-BE(2) cells treated with 1200 nM or same volume DMSO for 48 h were generated by RNA sequencing, in double, using Illumina NovaSeq6000.